Acelyrin (NASDAQ:SLRN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on ...

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

The Rights Plan is effective immediately and will expire on March 12, 2026. ACELYRIN stockholders do not need to take any further action at this time.

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs, daunting ...